Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2006

View Archived Issues

Satavaptan reduces paracenteses in cirrhotic patients with ascites

Double-blind trials detail activity of istradefylline in Parkinson's disease

Vandetanib reduces tumors in murine models of hepatocellular carcinoma

Positive preclinical results for SCY-635, a novel Scynexis anti-HCV candidate

Elan updates quarterly progress

AVIDA registry enrolling patients on Vidaza

Research supports study of molecular iodine in breast cancer

VASTox receives grant in support of spinal muscular atrophy program

IND cleared for study of rhMBL in liver transplant patients

Gladstone Institutes and Merck & Co. form apoE collaboration in neurodegeneration

Introgen gains license supporting combination of Advexin and EGFR inhibitors

AstraZeneca expands development plan for CytoFab

SPA agreement for pivotal study of StemEx

Inyx to manufacture Plethora's topical HFA aerosol for premature ejaculation

KB-2115 begins phase II for dyslipidemia

Pivotal study of MBP-8298 for MS expanded into Baltic countries

VaxGen's second phase II trial of rPA-102 delayed by clinical hold

Enrollment temporarily suspended in lung cancer study of Xyotax

Dutch Government invests in development of TB drugs

New data on effect of ZIO-201 on human pediatric sarcoma models

Microdosing/phase 0 trials: Paradigm shift aims to speed new drug development, improve efficiency

Prexige completes European mutual recognition procedure for osteoarthritis

Approvable letter for Entereg in postoperative ileus

Lorus presents novel pharmacokinetics data on GTI-2040 at the AAPS meeting

KRN-383, a novel Flt3 inhibitor, shows promise in murine models of AML

Positive preclinical data presented for PYM-50028 in Parkinson's disease

Beneficial effects of CB1 antagonism in models of Parkinson's disease

Recent patents report new therapeutic agents for anxiety, depression, sleep disorders, etc.

Recent Novo Nordisk and Roche patents disclose novel treatment strategies for obesity

Novel immunosuppressant agents disclosed by Pharmacopeia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...